{
    "clinical_study": {
        "@rank": "144644", 
        "arm_group": {
            "arm_group_label": "Transcutaneous Electrical Spinal Cord Stimulation", 
            "arm_group_type": "Experimental", 
            "description": "Determine improvement in upper limb function with Transcutaneous Electrical Spinal Cord Stimulation of the spinal cord with a Transcutaneous Electrical Spinal Cord Stimulator."
        }, 
        "brief_summary": {
            "textblock": "We will examine the use of transcutaneous electrical stimulation of the lumbosacral spinal\n      cord to: 1) assess spared function following a spinal cord injury; and, 2) use this same\n      paradigm for rehabilitation. We hypothesize that the spinal cord below the level of injury\n      can be activated to produce coordinated movement of the legs."
        }, 
        "brief_title": "Transcutaneous Electrical Spinal Cord Stimulation for Lower Limbs", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Cord Injury, Paralysis", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Paralysis", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Spinal cord injury 1 or more years prior\n\n          -  Non progressive cervical or thoracic SCI\n\n          -  Half of key muscles below neurological level having a motor score of less than 2/5\n\n          -  Ability to commit to home exercises and 18 week participation\n\n          -  Stable medical condition without cardiopulmonary disease or dysautonomia that would\n             contraindicate participation in lower extremity rehabilitation or testing activities\n\n          -  Not dependent on ventilation support\n\n          -  No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or urinary\n             tract infection that might interfere with lower extremity rehabilitation or testing\n             activities\n\n          -  No clinically significant depression or ongoing drug abuse\n\n          -  Adequate social support network to be able to participate in weekly training and\n             assessment sessions for the duration of the 18 week study period\n\n          -  No current anti-spasticity regimen\n\n          -  Must not have received botox injections in the prior six months\n\n          -  Be unable to use lower extremity for functional tasks\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  No functional segmental reflexes below the lesion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949285", 
            "org_study_id": "NETI201309"
        }, 
        "intervention": {
            "arm_group_label": "Transcutaneous Electrical Spinal Cord Stimulation", 
            "description": "A prototype device that transcutaneously delivers painless electrical stimulation to the spinal cord will be used to assess and rehabilitate spares spinal cord function.", 
            "intervention_name": "Transcutaneous Electrical Spinal Cord Stimulation", 
            "intervention_type": "Device", 
            "other_name": "Prototype Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Spinal cord injury", 
            "Paralysis", 
            "Rehabilitation", 
            "Assessment", 
            "Theranostics"
        ], 
        "lastchanged_date": "September 19, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Theranostic Tool to Assess and Enable Spared Spinal Motor Function After SCI", 
        "overall_contact": {
            "email": "dclu@mednet.ucla.edu", 
            "last_name": "Daniel C Lu, MD PhD", 
            "phone": "310-825-4321"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be tested by several measures of sensory and motor function, as well as self assessments of spasticity, quality of life, and independence. These tests include:\nAmerican Spinal Injury Association (ASIA) scoring system, Spinal Cord Independence Measure (SCIM), Ashworth Spasticity Scale, Penn Spasm Frequency, Visual Analog Scale (VAS) for Spasticity, Electromyographic (EMG) recordings, Joint angle (goniometer) measures, kinematic analysis.", 
            "measure": "Improvement in sensorimotor function in legs", 
            "safety_issue": "Yes", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "NeuroEnabling Technologies, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of California, Los Angeles", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "California Institute of Technology", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "NeuroEnabling Technologies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}